Key facts
- It has raised $500K; the latest was Seed Round in Oct 2025.
- Notable investors include Y Combinator, Gaingels, Rebel Fund, Maiora Ventures, Scoop Ventures — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Convexia
- ·The full record, as it builds
Funding rounds
No funding rounds for Convexia are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Convexia
Developer of AI-native pharmaceutical asset platforms designed to accelerate drug development through agent-based analysis. The company offers sourcing, in silico evaluation, human and market review, operational risk modeling, and business development workflows, enabling biotech operators to identify, validate, and prepare potential therapies for development and partnering.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2025
- Employees
- 2
- Website
- convexia.bio/
- Ownership
- Privately Held (backing)
Convexia doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Convexia shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Convexia in its N-PORT filings yet. We sweep new filings monthly.